$TEVA News

Teva's Re-Rating Still Has Room To Run

Teva Stock Rises After Earnings as Revenue Guidance Exceeds Expectations

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ...

Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call Transcript

Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing

Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss

Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

‘It is okay not to be okay’: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness

Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16.400B-$16.800B to $16.500B-$16.850B vs $16.618B Est

Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate

Stay Ahead of the Game With Teva Pharmaceutical Industries (TEVA) Q2 Earnings: Wall Street's Insights on Key Metrics

Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $44

Teva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progress

Teva (TEVA) Stock Looks Discounted On Cash Flow Yet Fair On Earnings

Teva Pharmaceutical Industries And Samsung Bioepis Partner To Commercialize OPUVIZ Aflibercept Biosimilar In Canada

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b Transcript

Teva Shared Data From Ongoing Phase 1b Study Of TEV-’408 Showing Improvements In Skin Pigmentation In Active Or Stable Non-Segmental Vitiligo Patients; Plans To Advance TEV-’408 Into Phase 2b Study In Vitiligo In Q4 2026